In Person
Innovative HIV Prevention and Treatment Keynote and Panel Discussion
Can a Twice-Yearly PrEP Injection Curb the HIV Pandemic? Join the O’Neill Institute for an in-depth discussion on Lenacapavir, a groundbreaking long-acting injectable PrEP formulation administered just twice a year. This session will examine its potential to transform HIV prevention on a global scale, looking at the latest clinical evidence, regulatory pathways, and the access…